Litigation Details for Triple-S Salud, Inc. v. Teva Pharmaceuticals USA, Inc. (N.D. Cal. 2021)
✉ Email this page to a colleague
Triple-S Salud, Inc. v. Teva Pharmaceuticals USA, Inc. (N.D. Cal. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-12-14 |
| Court | District Court, N.D. California | Date Terminated | |
| Cause | 15:1 Antitrust Litigation | Assigned To | Edward Milton Chen |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 6,043,230; 6,639,071; 6,642,245; 6,703,396; 6,939,964 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Triple-S Salud, Inc. v. Teva Pharmaceuticals USA, Inc.
Biologic Drugs cited in Triple-S Salud, Inc. v. Teva Pharmaceuticals USA, Inc.
The biologic drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Triple-S Salud, Inc. v. Teva Pharmaceuticals USA, Inc. (N.D. Cal. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-12-14 | 1 | Complaint | and 6,043,230 (“the ’230 patent”) — all derived from the same patent application and 27 7 … the patents — U.S. Patents Nos. 5,922,695 (“the ’695 patent”), 5,977,089 (“the ’089 26 patent”), and…infringing U.S. Patent Nos. 6,639,071 (the “’071 patent”) and 9 6,939,964 (the “’964 patent”). BMS was …include U.S. Patent Nos. 6,642,245 (“the ’245 patent”) and 6,703,396 (“the ’396 18 patent”). The FTC …Emory’s patents (the ’639, ’245, and ’396 patents), along with 6 Emory’s related U.S. Patent No. 5, | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
